QTc interval in infants receiving cisapride

被引：5

作者：

Chhina S. ^{[1
]}

Peverini R.L. ^{[2
]}

Deming D.D. ^{[2
]}

Hopper A.O. ^{[2
]}

Hashmi A. ^{[3
]}

Vyhmeister N.R. ^{[2
]}

机构：

[1] Doctor’s Hospital, Laredo, TX

[2] Division of Neonatology, Department of Pediatrics, Loma Linda University School of Medicine, Loma Linda, CA

[3] Division of Pediatric Cardiology, Department of Pediatrics, Loma Linda University School of Medicine, Loma Linda, CA

来源：

Journal of Perinatology | 2002年 / 22卷 / 2期

关键词：

D O I：

10.1038/sj.jp.7210613

中图分类号：

学科分类号：

摘要：

Objective: To examine the effect of cisapride on the corrected QT (QTc) interval in infants over a 14-day period. Study Design: A prospective cohort study of infants receiving cisapride (0.8 mg/kg per day). Twelve-lead electrocardiograms were obtained before and 3, 5, 7, and 14 days after cisapride initiation. Results: Fifty infants completed the study; none had arrhythmias. Fifteen of 50 infants (30%) developed QTc interval ≥450 msec; QTc interval normalized in 13 of 15 infants. Infants with QTc interval on day 3≥2 standard deviations above the mean baseline QTc interval (401+40 msec) were more likely to develop prolonged QTc interval (p<0.0001). Conclusion: QTc interval prolongation was noted in 30% of infants. Subsequently, the majority of those infants had QTc interval normalization by day 14 of cisapride therapy. QTc interval 3 days following cisapride initiation may identify infants at risk for transient QTc interval prolongation. With appropriate monitoring, hospitalized infants receiving cisapride may have improved gastrointestinal motility without cardiac morbidity.

引用

页码：144 / 148

页数：4

共 32 条

[1]

Ariagno R.L., Kikkert M.A., Mirmiran M., Conrad C., Baldwin R.B., Cisapride decreases gastroesophageal reflux in preterm infants, Pediatrics, 107, (2001)

[2]

Lander A., Redkar R., Nicholls G., Lawson A., Choudhury S.R., Corkery J.J., Et al., Cisapride reduces neonatal postoperative ileus: Randomised placebo controlled trial, Arch. Dis. Child. Fetal. Neonat. Ed., 77, pp. F119-F122, (1997)

[3]

Marcon M.A., Advances in the diagnosis and treatment of gastroesophageal reflux disease, Curr. Opin. Pediatr., 9, pp. 490-493, (1997)

[4]

Vandenplas Y., Ashkenazi A., Belli D., Boige N., Bouquet J., Cadranel S., Et al., A proposition for the diagnosis and treatment of gastro-oesophageal reflux disease in children: A report from a working group on gastrooesophageal reflux disease, Eur. J. Pediatr., 152, pp. 704-711, (1993)

[5]

Vandenplas Y., Belli D., Benhamou P.H., Cadranel S., Cezard J.P., Cucchiara S., Et al., Current concepts and issues in the management of regurgitation of infants: A reappraisal. Management guidelines from a working party, Acta. Paediatr., 85, pp. 531-534, (1996)

[6]

Cucchiara S., Cisapride therapy for gastrointestinal disease, J. Pediatr. Gastroenterol. Nutr., 22, pp. 259-269, (1996)

[7]

Weaver L.T., Lucas A., Development of gastrointestinal structure and function, Neonatal Nutrition and Metabolism, pp. 71-90, (1991)

[8]

Berseth C.L., Gastrointestinal motility in the neonate, Clin. Perinatol., 23, pp. 179-190, (1996)

[9]

Enriquez A., Bolisetty S., Patole S., Garvey P.A., Campbell P.J., Randomised controlled trial of cisapride in feed intolerance in preterm infants, Arch. Dis. Child. Fetal. Neonat. Ed., 79, pp. F110-F113, (1998)

[10]

Carroccio A., Iacono G., Li Voti G., Montalto G., Cavataio F., Tulone V., Et al., Gastric emptying in infants with gastroesophageal reflux. Ultrasound evaluation before and after cisapride administration, Scand. J. Gastroenterol., 27, pp. 799-804, (1992)

← 1 2 3 4 →